Re: Farmas USA
mugiwara, compañero de camino
DVAX
Otro Pum-pum de SA y ya en Pre en +2%
Es verdad que el Short Interest ha caido eso vale mas q esta art pero en esta la veo en 36 en primero PO que habie leido por ahi antes de finales de Septiembre y por el camino nos van a soplar un par de dilciones mas a precios cada vez mas altos, apensa tenemos 38.9 share float con 69 % de institucionales segun NASDAQ y 80% segun FINVAZ
http://finviz.com/quote.ashx?t=DVAX
http://www.nasdaq.com/symbol/dvax/ownership-summary
--
The $4Bn Patient; Will Dynavax Study Finally Remove Safety Doubts From Heplisav
There are existing vaccines for HBV, marketed as Engerix-B® (from GSK) and Recombivax HB® (from Merck(; the annual market for these two products is estimated at $1 Bn
Heplisav is better than existing treatments in 3 ways: ((i))) it is more effective at its maximum, ((ii)) it is easier to administer - requiring less visits to the clinic, and ((iii)) it has a higher potential for compliance since less individuals will receive only partial protection.
The apparent advantage of this vaccination treatment has brought analysts to predict that Heplisav will dominate the HBV vaccine market and they, as well as the company project annual revenues of $600 M
http://seekingalpha.com/article/3435886-the-4bn-patient-will-dynavax-study-finally-remove-safety-doubts-from-heplisav?app=1&auth_param=ft8lg:1asp4ja:a8b07078ca2867a71a41256970a5f861&uprof=37
---
Our general insight from this would be that when making investment decisions in biotech stocks, remember that safety of the drug should always be considered, at least as important as efficacy, especially when other alternatives are in the market.
--
Lo que mientras mas la pumpeam mas miedo y mas cerca veo el Bears Raid.".